MarketPulse
R

$ROIV

6 articles found
4 positive
0 negative
2 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Myasthenia Gravis Market Poised for Transformation With 8 Late-Stage Drug Candidates

Generalized myasthenia gravis market valued at $5.9B in 2025, projected to grow 9.1% annually through 2036 as eight promising late-stage therapies advance.
NVSAZNREGNMKKGYROIV+3clinical trialsautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Priovant Advances Rare Disease Pipeline with Fourth Brepocitinib Indication

Priovant initiates Phase 2b/3 trial for brepocitinib in lichen planopilaris, marking fourth indication; dermatomyositis FDA decision expected Q3 2026.
ROIVFDA approvalrare disease
GlobeNewswire Inc.GlobeNewswire Inc.··Priovant Therapeutics / Roivant Sciences

Priovant's Brepocitinib Clears Phase 3 Trial for Rare Muscle Disease, Eyes 2026 FDA Approval

Priovant's brepocitinib met Phase 3 endpoints for dermatomyositis treatment, earning FDA Priority Review with Q3 2026 decision expected.
ROIVclinical trial resultsautoimmune disease
Investing.comInvesting.com··David Wagner

Moderna's $2.25B Settlement Clears Patent Cloud as Biotech Sector Eyes Deep Value Opportunities

Moderna settles $2.25B patent dispute, surges 15.99%. Analysis identifies 9 biotech stocks trading 27-65% below fair value with 31-251% upside potential.
MRNAROIVABUSfair valueundervalued
BenzingaBenzinga··Vandana Singh

Moderna Settles $950M Patent Dispute, Clears Path for Profitability Push

Moderna settles $950M patent dispute with Arbutus and Genevant, clearing legal uncertainty. Stock surges 8.85% as company targets 2028 breakeven with $4.5-5B cash by 2026.
MRNABNTXROIVABUSbalance sheet strengthmRNA technology
The Motley FoolThe Motley Fool··Jonathan Ponciano

Healthcare REIT Achieves Double-Digit NOI Growth as Investor Confidence Strengthens

Healthcare REIT posts 16.4% NOI growth with strong senior housing demand. Stock surged 93% as management raises full-year guidance amid improving occupancy rates.
NVDAAHRDLBROIVcapital allocationhealthcare REIT